Novel glycosaminoglycan biosynthetic inhibitors affect tumor-associated angiogenesis

Biochemical and Biophysical Research Communications

Volumn 404, Issue 1, 2011, Pages 86-89

  Raman, Karthik ^a   Ninomiya, Masayuki ^b   Nguyen, Thao Kim Nu ^a   Tsuzuki, Yasuhiro ^b   Koketsu, Mamoru ^b   Kuberan, Balagurunathan ^a,c,d  

^a Department of Electrical and Computer Engineering   (United States)

^b GIFU UNIVERSITY   (Japan)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Angiogenesis; Heparan sulfate; Inhibitor; Matrigel; Proteoglycan; Xyloside

Indexed keywords

ANGIOGENESIS INHIBITOR; GLYCOSAMINOGLYCAN; MATRIGEL; SULFORAPHANE; UNCLASSIFIED DRUG; XYLOSIDE III; XYLOSIDE IV;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEOGLYCAN SYNTHESIS; SIMULATION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CATTLE; ENDOTHELIAL CELLS; GLYCOSIDES; HEPARAN SULFATE PROTEOGLYCANS; MICROVESSELS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 78650911606     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.069     Document Type: Article

References (25)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
2. Raman K., Kuberan B. Chemical tumor biology of heparan sulfate proteoglycans. Curr. Chem. Biol. 2010, 4:20-31.
3. Sanderson R.D., Yang Y., Kelly T., MacLeod V., Dai Y., Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J. Cell. Biochem. 2005, 96:897-905.
4. Sasisekharan R., Ernst S., Venkataraman G. On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans. Angiogenesis 1997, 1:45-54.
5. Folkman J., Klagsbrun M., Sasse J., Wadzinski M., Ingber D., Vlodavsky I. A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am. J. Pathol. 1988, 130:393-400.
6. Klagsbrun M. Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. Semin. Cancer Biol. 1992, 3:81-87.
7. Nakato H., Kimata K. Heparan sulfate fine structure and specificity of proteoglycan functions. Biochim. Biophys. Acta 2002, 1573:312-318.
8. Gama C.I., Hsieh-Wilson L.C. Chemical approaches to deciphering the glycosaminoglycan code. Curr. Opin. Chem. Biol. 2005, 9:609-619.
9. Guimond S., Maccarana M., Olwin B.B., Lindahl U., Rapraeger A.C. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J. Biol. Chem. 1993, 268:23906-23914.
10. Sugaya N., Habuchi H., Nagai N., Ashikari-Hada S., Kimata K. 6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signallings in culture. J. Biol. Chem. 2008, 283:10366-10376.
11. Lundin L., Larsson H., Kreuger J., Kanda S., Lindahl U., Salmivirta M., Claesson-Welsh L. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J. Biol. Chem. 2000, 275:24653-24660.
12. Victor X.V., Nguyen T.K., Ethirajan M., Tran V.M., Nguyen K.V., Kuberan B. Investigating the elusive mechanism of glycosaminoglycan biosynthesis. J. Biol. Chem. 2009, 284:25842-25853.
13. Lugemwa F.N., Esko J.D. Estradiol beta-d-xyloside, an efficient primer for heparan sulfate biosynthesis. J. Biol. Chem. 1991, 266:6674-6677.
14. Bourdon M.A., Krusius T., Campbell S., Schwartz N.B., Ruoslahti E. Identification and synthesis of a recognition signal for the attachment of glycosaminoglycans to proteins. Proc. Natl. Acad. Sci. USA 1987, 84:3194-3198.
15. Schwartz N.B., Galligani L., Ho P.L., Dorfman A. Stimulation of synthesis of free chondroitin sulfate chains by beta-d-xylosides in cultured cells. Proc. Natl. Acad. Sci. USA 1974, 71:4047-4051.
16. Henke C.A., Roongta U., Mickelson D.J., Knutson J.R., McCarthy J.B. CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. J. Clin. Invest. 1996, 97:2541-2552.
17. Brule S., Friand V., Sutton A., Baleux F., Gattegno L., Charnaux N. Glycosaminoglycans and syndecan-4 are involved in SDF-1/CXCL12-mediated invasion of human epithelioid carcinoma HeLa cells. Biochim. Biophys. Acta 2009, 1790:1643-1650.
18. Raman K., Kuberan B. Click-xylosides mitigate glioma cell invasion in vitro. Mol. BioSyst. 2010, 6:1800-1802.
19. Mani K., Belting M., Ellervik U., Falk N., Svensson G., Sandgren S., Cheng F., Fransson L.A. Tumor attenuation by 2(6-hydroxynaphthyl)-beta-d-xylopyranoside requires priming of heparan sulfate and nuclear targeting of the products. Glycobiology 2004, 14:387-397.
20. Garud D.R., Tran V.M., Victor X.V., Koketsu M., Kuberan B. Inhibition of heparan sulfate and chondroitin sulfate proteoglycan biosynthesis. J. Biol. Chem. 2008, 283:28881-28887.
21. Raman K., Kuberan B. Differential effects of Heparitinase I and Heparitinase III on endothelial tube formation in vitro. Biochem. Biophys. Res. Commun. 2010, 398:191-193.
22. Tsuzuki Y., Nguyen T.K.N., Garud D.R., Kuberan B., Koketsu M. 4-Deoxy-4-fluoro-xyloside derivatives as inhibitors of glycosaminoglycan biosynthesis. Bioorg. Med. Chem. Lett. 2010, 20:7269-7273.
23. Rosen L.S. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002, 9:36-44.
24. Tran V.M., Victor X.V., Yockman J.W., Kuberan B. RGD-xyloside conjugates prime glycosaminoglycans. Glycoconj. J. 2010, 27:625-633.
25. Rosen S.D. Ligands for L-selectin: homing, inflammation, and beyond. Annu. Rev. Immunol. 2004, 22:129-156.